Nephrotic syndrome during treatment with alpha-mercaptopropionylglycine.
We report 2 cases of cystinuria in which a nephrotic syndrome developed during treatment with alpha-mercaptopropionylglycine. This syndrome resolved after withdrawal of the drug and it did not recur when the alpha-mercaptopropionylglycine was given again in lower doses. The hypothesis is made that the nephrotic syndrome was dose-related. The alpha-mercaptopropionylglycine must be used in doses less than 50 mg./kg per day with regular monitoring of 24-hour urinary protein in cystinuric children.
D000603:Amino Acids, Sulfur / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003555:Cystinuria / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced*; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D008625:Tiopronin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000603:Amino Acids, Sulfur; D008625:Tiopronin